Publication Name	World Journal of Gastroenterology
Manuscript ID	6574
Country	Taiwan

Received	2013-10-24 15:31
Peer-Review Started	2013-10-25 18:11
To Make the First Decision	2013-11-21 21:02
Return for Revision	2013-11-22 09:40
Revised	2013-12-13 19:38
Second Decision	2014-05-26 16:18
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-05-26 16:37
Articles in Press	2014-05-26 17:39
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-06-13 15:03
Publish the Manuscript Online	2014-06-27 10:37

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues
Manuscript Source	Invited Manuscript
All Author List	Chien-Hung Chen, Yi-Chun Chiu, Sheng-Nan Lu, Chuan-Mo Lee, Jing-Houng Wang, Tsung-Hui Hu and Chao-Hung Hung
Funding Agency and Grant Number
Corresponding Author	Chao-Hung Hung, MD, Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung 833, Taiwan. chh4366@yahoo.com.tw
Key Words	Alanine aminotransferase; Hepatitis B virus; Hepatitis B surface antigen; Nucleos(t)ide analogs; Virological response
Core Tip	Patients receiving nucleos(t)ide analog (NA) treatment typically exhibit slow declines in serum hepatitis B surface antigen (HBsAg), with many patients requiring decades of treatment to achieve HBsAg clearance. However, a low baseline HBsAg level or a rapid reduction in HBsAg during NA therapy may identify patients who will show HBsAg clearance, and predict virological response or hepatitis B e antigen (HBeAg) loss/seroconversion in HBeAg-positive patients. Viral breakthrough due to drug resistance can increase HBsAg titers. Among Asian patients, HBsAg levels of < 100-200 IU/mL at the end of treatment may predict lower risk of hepatitis B virus relapse and cessation of treatment can be considered in HBeAg-negative patients.
Publish Date	2014-06-27 10:37
Citation	Chen CH, Chiu YC, Lu SN, Lee CM, Wang JH, Hu TH, Hung CH. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol 2014; 20(24): 7686-7695
URL	http://www.wjgnet.com/1007-9327/full/v20/i24/7686.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i24.7686

Full Article (PDF)	WJG-20-7686.pdf
Full Article (Word)	WJG-20-7686.doc
Manuscript File	6574-Review.docx
Answering Reviewers	6574-Answering reviewers.pdf
Copyright License Agreement	6574-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	6574-Language certificate.pdf
Peer-review Report	6574-Peer review(s).pdf
Scientific Misconduct Check	6574-CrossCheck.jpg
Scientific Editor Work List	6574-Scientific editor work list.pdf